Feature | Contrast Media | July 28, 2015

Guerbet Group Acquires Mallinckrodt Contrast Media and Delivery Systems Business

Acquisition complements Guerbet Group's offerings in X-ray and MRI

Guerbet, acquisition, Mallinckrodt, CMDS business, contrast media, CT, MRI

July 28, 2015 — Guerbet announced that it has entered into a definitive agreement under which it will acquire Mallinckrodt's contrast media and delivery systems business ("CMDS").

The pro forma combined sales of Guerbet and the CMDS business were close to €800M in 2014 with a global workforce of around 2,500.

This competitive acquisition process has been conducted by Guerbet's management under the supervision of Guerbet's board of directors and its strategic committee. Guerbet has been advised in this process by Lazard and Gide Loyrette Nouel, respectively, as financial and legal advisors. The due diligence has been conducted in collaboration with PwC.

The key strengths of the CMDS business identified by Guerbet are:

  • An efficient industrial and commercial platform with four production sites in Ireland and in North America and a global distribution network covering approximately 65 countries;
  • A comprehensive range of delivery systems and imaging solutions for X-ray scanners, X-ray cardiac and vascular imaging, urological imaging and magnetic resonance imaging; and
  • A large portfolio of patents and other intellectual property rights.


For the first six months of fiscal 2015, Mallinckrodt's CMDS business recorded sales of close to $210 million.

Guerbet is acquiring 100 percent of the CMDS business including the production sites, the intellectual property rights and the distribution subsidiaries in the various geographical areas, in a transaction valued approximately $270 million, entirely paid in cash and financed through term loan facilities syndicated by BNP Paribas.

In connection with this acquisition, Guerbet will be in a position to finance additional investments in an amount of $50M, will refinance its existing debt and benefit from a revolving credit facility in order to finance its additional working capital requirements.

Consequently Guerbet pro forma net debt/EBITDA ratio could temporarily rise to a multiple of more than three before returning rapidly to a ratio of less than two. 

The transaction is subject to customary closing conditions and is expected to close in the next few months.

Guerbet's works council has unanimously issued a favorable opinion in respect of the acquisition of the CMDS business.

The CMDS business will complement the group’s historic business units in several ways:

  • In contrast media, the CMDS business is well positioned with Optiray and Optiject (Europe)/Ultraject (United States) in X-ray, whereas Guerbet holds a similar position in MRI with Dotarem;
  • In imaging solutions and services, this acquisition will open up technological synergies, with the CMDS business mastering syringe-based delivery systems and Guerbet the innovative hydraulic injection technique for softbags;
  • The businesses are also geographically highly complementary, with the CMDS business holding a strong position in the United States and Guerbet likewise in Europe. The operation will enable Guerbet to accelerate Dotarem commercial success in the United States and envisage a much quicker launch of the Group's new products around the world. Guerbet will also reinforce its presence in high growth potential markets including China, Russia and Turkey.


Lastly, the growth of sales is expected to increase production volumes and reduce costs through a better absorption of fixed expenses.

For more information: www.guerbet.com

Related Content

Median Technologies and the Nice University Hospital to Use AI in Lung Cancer Screening
News | Artificial Intelligence | March 15, 2018
March 15, 2018 – Median Technologies, the industry-leading Imaging Phenomics Company and the Nice University Hospital
Siemens Healthineers Launches New Partners for Digital Ecosystem at HIMSS 2018
News | PACS Accessories | March 12, 2018
At the 2018 Healthcare Information and Management Systems Society (HIMSS) Annual Conference and Exhibition, March 5-9...
Alternative Technique Can Improve Brain Imaging for Restless Children
News | Pediatric Imaging | March 08, 2018
March 8, 2018 – Children often find it difficult to remain still for...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain.

This figure shows two different brains that are aligned to a common template space for comparison. The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain. CREDIT: Zachariah Reagh

News | Nuclear Imaging | March 08, 2018
As we get older, it's not uncommon to experience "senior moments," in which we forget where we parked our car or call...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...
Designed to optimize workflow, IntelliSpace Portal supports consistency across applications.
Sponsored Content | Case Study | Imaging | March 06, 2018
As one of the largest Catholic, not-for-profit healthcare systems in the United States, St. Louis-based SSM Health has...
TriHealth in Cincinnati

TriHealth in Cincinnati.

Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018
The continuing search for advantages to improve workflow has radiology departments constantly searching for new...
Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018
News | Contrast Media | February 28, 2018
February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other...
Overlay Init